Mary Guan
Tracked across 1 events · 6 articles · First seen Jul 02, 2026 · Last active Jul 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Mary Guan, General Manager of AstraZeneca China Oncology Business, underscored the approval of ORPATHYS (savolitinib) as a pivotal chapter in the joint development journey with HUTCHMED, reinforcing their shared vision for precision medicine.
Jul 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Mary Guan live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard